Bronchial Arterial Infusion Is an Effective Therapeutic Modality for Centrally Located Early-Stage Lung Cancer

Osaki, Toshihiro; Hanagiri, Takeshi; Nakanishi, Ryoichi; Yoshino, Ichiro; Taga, Satoshi; Yasumoto, Kosei

doi:10.1378/chest.115.5.1424

Cited by 48 publications

(36 citation statements)

References 14 publications

Supporting

Mentioning

Contrasting

Unclassified

Order By: Relevance

“…Kogure et al reported that TAI combined with simultaneous BAI can achieve CR, even in cases involving primary HCC lesions (26). All seven cases exhibited beneficial outcomes without adverse respiratory effects following therapy with cisplatin at a dose up to 80 mg in BAI, whereas a higher dose often results in the formation of bronchial ulcers (29). Although sufficient evidence is not yet available regarding the effects of BAI for pulmonary metastasis of HCC, this treatment is nevertheless considered to be a potentially effective modality in such cases.…”

Section: Discussionmentioning

confidence: 98%

Successful Treatment of Hepatocellular Carcinoma with Lung Metastasis Using Hepatic and Bronchial Artery Infusion Chemotherapy

et al. 2014

View full text Add to dashboard Cite

We herein report a case of hepatocellular carcinoma (HCC) with lung metastasis that was successfully treated with transcatheter arterial infusion chemotherapy via the hepatic and bronchial arteries. A 64-year-old man diagnosed with HCC in 2003 was treated with locoregional therapy followed by sorafenib for recurrent HCC. Tumor thrombosis and lung metastasis were noted in April 2012. We administered IA-call , a finepowder formulation of cisplatin, via the hepatic and bronchial arteries. This therapy resulted in the disappearance of the lung metastases and a partial response to tumor thrombosis. The patient remained alive for 23 months after developing lung metastasis.

show abstract

Section: Discussionmentioning

confidence: 98%

Successful Treatment of Hepatocellular Carcinoma with Lung Metastasis Using Hepatic and Bronchial Artery Infusion Chemotherapy

et al. 2014

View full text Add to dashboard Cite

show abstract

“…Although BAI therapy is not a new therapy and has not achieved wide acceptance as a standard clinical therapy for lung cancer due to its unconfirmed outcomes and severe side-effects, including esophageal ulceration and spinal cord damage, several studies have indicated that it should be reappraised as a preoperative adjuvant therapy for advanced lung cancer as it has been observed histopathologically to have a high response (7,8,18,19). In the studies carried out by Nakanishi et al, many feeding arteries (including bronchial and nonbronchial systemic arteries) in patients with NSCLC were detected and the grade of total tumor staining was significantly higher than that of tumor staining supplied by the bronchial artery.…”

Section: Discussionmentioning

confidence: 99%

“…Arteries with tumor staining revealed by angiography were regarded as feeding arteries. Multi-arterial infusion was based on gemcitabine and cisplatin as a first-line therapy (8,18). We divided the total dose among the detected feeding arteries according to the degree of tumor staining in each artery.…”

Section: Detection Of Lung Cancer Feeding Arteries By Conventional Anmentioning

confidence: 99%

Assessment of the feeding arteries by three-dimensional computed tomography angiography prior to multi-arterial infusion chemotherapy for lung cancer

Ye¹,

Zheng²,

Ye³

et al. 2012

Oncology Letters

View full text Add to dashboard Cite

Abstract. The aim of this study was to evaluate the efficacy of multi-detector row helical computed tomography (MDCT) angiography in the detection of feeding arteries prior to multi-arterial infusion for lung cancer. A total of 59 consecutive patients (44 males and 15 females; age range, 27-86 years; median age, 62 years) with non-small cell lung cancer underwent MDCT angiography of the thorax prior to multi-arterial infusion for lung cancer. Findings on CT angiograms, including CT scans, maximum intensity projections and three-dimensional volume-rendered images, were used to evaluate the depiction of bronchial and non-bronchial systemic arteries. The results of detecting the feeding arteries for lung cancer by MDCT angiography and conventional angiography were compared. Among the 59 patients treated with multi-arterial infusion chemotherapy, a total of 80 feeding arteries (62 bronchial feeding arteries and 18 non-bronchial systemic arteries) were detected by conventional angiography and/or MDCT angiography. In 56 (70%) feeding arteries (including 44 bronchial feeding arteries and 12 non-bronchial systemic arteries) for lung cancers, concordant findings were observed with the two modalities. In 23 (29%) cases, MDCT angiography could not be used to define feeding arteries, but was used to identify the ostia of these feeding arteries. In one (1/80, 1.3%) case, the CT-defined feeding artery was not selectively catheterized. MDCT angiography of the chest is able to provide an overview for successful catheterization in multi-arterial infusion chemotherapy for lung cancer.

show abstract

“…11,12 Nevertheless, drugs already being used for systemic administration have been successfully administered regionally in various types of cancer. [13][14][15][16][17][18][19][20][21][22][23] The concept of local drug delivery is proposed as a method for delivering high drug concentrations to the target site while preventing exposure of vital organs to toxic drug concentrations in the systemic circulation. In this way, systemic side effects are minimized.…”

Section: Introductionmentioning

confidence: 99%

Inhaled chemotherapy in lung cancer: future concept of nanomedicine

Zarogoulidis

Chatzaki²,

Porpodis³

et al. 2012

IJN

168

160

View full text Add to dashboard Cite

Regional chemotherapy was first used for lung cancer 30 years ago. Since then, new methods of drug delivery and pharmaceuticals have been investigated in vitro, and in animals and humans. An extensive review of drug delivery systems, pharmaceuticals, patient monitoring, methods of enhancing inhaled drug deposition, safety and efficacy, and also additional applications of inhaled chemotherapy and its advantages and disadvantages are presented. Regional chemotherapy to the lung parenchyma for lung cancer is feasible and efficient. Safety depends on the chemotherapy agent delivered to the lungs and is dose-dependent and time-dependent. Further evaluation is needed to provide data regarding early lung cancer stages, and whether regional chemotherapy can be used as neoadjuvant or adjuvant treatment. Finally, inhaled chemotherapy could one day be administered at home with fewer systemic adverse effects.

show abstract

Bronchial Arterial Infusion Is an Effective Therapeutic Modality for Centrally Located Early-Stage Lung Cancer

Cited by 48 publications

References 14 publications

Successful Treatment of Hepatocellular Carcinoma with Lung Metastasis Using Hepatic and Bronchial Artery Infusion Chemotherapy

Successful Treatment of Hepatocellular Carcinoma with Lung Metastasis Using Hepatic and Bronchial Artery Infusion Chemotherapy

Assessment of the feeding arteries by three-dimensional computed tomography angiography prior to multi-arterial infusion chemotherapy for lung cancer

Inhaled chemotherapy in lung cancer: future concept of nanomedicine

Contact Info

Product

Resources

About